Medication info
Rivaroxaban 2/160 mg

Rivaroxaban 2/160 mg

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium Hydrate›2mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
Pink rectangular film-coated tablet
Packaging
30 tablets (6 tablets/PTP x 5)
Approval status
Active

MFDS item code 201500966 · Approved 2015.02.25 · Insurance code 644913920

Summary

Main use
Improvement of dyslipidemia, treatment of hypertension and heart failure, reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
This product should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, pitavastatin calcium and valsartan. This product should be taken once daily after breakfast. As aminotransferase levels may increase during treatment with this product, liver function tests should be performed before and during treatment. Liver function tests should be performed at least once within 12 weeks of starting treatment and periodically thereafter (e.g., once every 6 months). Particular caution should be exercised in patients with elevated serum aminotransferase levels, and liver function tests should be performed promptly and frequently. Pitavastatin calcium Patients should follow a standard cholesterol-lowering diet before and during treatment with this product. The usual initial dose for adults is 1~2 milligrams of pitavastatin calcium once daily. If the reduction in LDL-cholesterol levels is insufficient, the dose may be increased to a maximum of 4 milligrams daily. Depending on LDL-cholesterol levels, treatment goals, and patient response, the dose should be adjusted as appropriate at intervals of 4 weeks or longer. The therapeutic effect of this product is maintained with continued treatment. Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the product be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this product once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this product once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this product. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this product once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this product once daily; the dose should not exceed 80 mg daily. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this product orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this product, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this product twice daily, followed by dose increases over the next several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This product may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for a creatinine clearance of 10 mL/min or more. However, this product should not be administered to patients with a creatinine clearance of less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this product should preferably not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis. Patients taking pitavastatin calcium and valsartan concomitantly may switch to this product (a combination product containing the same amount of each active ingredient) for convenience.
Child dose
Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Improvement of dyslipidemia, treatment of hypertension and heart failure, reduction of the risk of death after myocardial infarction

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated apo-B protein
  • elevated triglycerides
  • essential hypertension
  • heart failure
  • intolerance to heart failure
  • left ventricular failure
View approved original text

This medication is used for patients who require concurrent administration of two drugs, pitavastatin calcium and valsartan. Pitavastatin calcium primarily lowers total cholesterol, bad cholesterol (LDL), apo-B protein, and triglyceride levels in patients with primary hypercholesterolemia and mixed dyslipidemia, while increasing good cholesterol (HDL) to assist with dietary therapy. Valsartan is used for the treatment of essential hypertension and is also effective in patients with heart failure and those intolerant to ACE inhibitors (NYHA class II-IV). Additionally, it helps reduce the risk of mortality in patients with impaired left ventricular function after myocardial infarction. Therefore, this medication is used to improve the treatment of patients with hypertension, heart failure, and concomitant dyslipidemia.

How to take

Adult dose

This product should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, pitavastatin calcium and valsartan. This product should be taken once daily after breakfast. As aminotransferase levels may increase during treatment with this product, liver function tests should be performed before and during treatment. Liver function tests should be performed at least once within 12 weeks of starting treatment and periodically thereafter (e.g., once every 6 months). Particular caution should be exercised in patients with elevated serum aminotransferase levels, and liver function tests should be performed promptly and frequently. Pitavastatin calcium Patients should follow a standard cholesterol-lowering diet before and during treatment with this product. The usual initial dose for adults is 1~2 milligrams of pitavastatin calcium once daily. If the reduction in LDL-cholesterol levels is insufficient, the dose may be increased to a maximum of 4 milligrams daily. Depending on LDL-cholesterol levels, treatment goals, and patient response, the dose should be adjusted as appropriate at intervals of 4 weeks or longer. The therapeutic effect of this product is maintained with continued treatment. Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the product be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this product once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this product once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this product. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this product once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this product once daily; the dose should not exceed 80 mg daily. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this product orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this product, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this product twice daily, followed by dose increases over the next several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This product may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for a creatinine clearance of 10 mL/min or more. However, this product should not be administered to patients with a creatinine clearance of less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this product should preferably not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis. Patients taking pitavastatin calcium and valsartan concomitantly may switch to this product (a combination product containing the same amount of each active ingredient) for convenience.

Child dose

Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication should not be used by pregnant women or women who may become pregnant. Taking this medication during pregnancy can cause serious harm to the fetus, so it should be discontinued immediately upon confirmation of pregnancy. Also, nursing mothers are advised not to take this medication, and if it is necessary to take it, breastfeeding should be discontinued. Patients with allergies to this medication, severe impairment of liver or kidney function, or certain genetic diseases should not use it. Elderly patients or those with compromised liver function should be particularly cautious when using this medication, and dosage should be adjusted if necessary. Blood pressure may drop sharply, so start with a low dose when first taking it, and closely monitor the patient's condition. If symptoms such as muscle pain, weakness, or darkening of urine occur, consult a doctor immediately and discontinue the medication if they occur. Regular liver function and blood tests are important as liver function abnormalities or abnormal blood test values may occur. When taking this medication with others, interactions may occur, so it is essential to inform your doctor or pharmacist of any other medications currently being taken, especially when combined with diuretics, potassium supplements, certain antibiotics, and immunosuppressants. This medication has not been established as safe for children and should not be used. In case of overdose, symptoms such as hypotension, decreased consciousness, and shock can occur, so immediate medical treatment should be sought. This medication should be stored out of the reach of children, and it is safe not to transfer the medication to another container.

Side effects

Headache, dyspepsia, nausea, serum AST elevation, chest discomfort, increased sweating, dizziness, abdominal pain, rash, fatigue, paralysis, itching, γ-GT elevation, increased plasma creatine phosphokinase levels, serum ALT elevation, serum AST elevation, rhabdomyolysis, myalgia, weakness, liver dysfunction, jaundice, thrombocytopenia, urticaria, erythema, angioedema, elevated bilirubin, increased cholinesterase, rigidity, drowsiness, insomnia, heaviness in the head, thirst, abdominal distension, constipation, stomatitis, vomiting, loss of appetite, glossitis, thrombocytopenia, granulocytopenia, leukocytopenia, eosinophilia, leukocytosis, elevated globulin, anemia, polyuria, elevated BUN, increased serum creatinine, decreased aldosterone, increased aldosterone, elevated adrenocorticotropic hormone, elevated cortisol, decreased testosterone, muscle cramps, elevated CPK, weakness, palpitations, fatigue, dermal pain, burning sensation, arthralgia, edema, blurred vision, photophobia, hearing loss, hematuria, elevated uric acid levels, elevated serum potassium and phosphorus, taste disorders, fatigue, positive antinuclear antibodies, sleep disorders, amnesia, depression, interstitial lung disease, sexual dysfunction, diabetes, immune-mediated necrotizing myopathy, myasthenia gravis, ocular myasthenia, facial edema, arm edema, hypersensitivity, skin paresthesia, insomnia, loss of appetite, elevated blood pressure, weakness, thirst, diarrhea, increased γ-GT, elevated LDH, increased ALP, urticaria, thrombocytopenia, increased serum creatinine, elevated BUN, tinnitus, tension increase, reduced motor function, confusion, chest pain, erythema, vasculitis, hepatitis, hypoglycemia, shock, syncope, loss of consciousness, vesicular dermatitis, intestinal vascular edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not let light in. It is also recommended to store the medication at a normal room temperature between 1 to 30 degrees Celsius, not in excessively hot or cold places.

Appearance and packaging

Appearance

Pink rectangular film-coated tablet

Package unit

30 tablets (6 tablets/PTP x 5)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.